Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct;55(4):1281-1290.
doi: 10.4143/crt.2023.479. Epub 2023 Jun 7.

Differential Perspectives by Specialty on Oligometastatic Colorectal Cancer: A Korean Oligometastasis Working Group's Comparative Survey Study

Won Kyung Cho  1 , Gyu Sang Yoo  1 , Chai Hong Rim  2 , Jae-Uk Jeong  3 , Eui Kyu Chie  4 , Yong Chan Ahn  1 , Hyeon-Min Cho  5 , Jun Won Um  6 , Yang-Gun Suh  7 , Ah Ram Chang  8 , Jong Hoon Lee  9 ; Oligometastasis Working Group, Korean Cancer Association
Affiliations

Differential Perspectives by Specialty on Oligometastatic Colorectal Cancer: A Korean Oligometastasis Working Group's Comparative Survey Study

Won Kyung Cho et al. Cancer Res Treat. 2023 Oct.

Abstract

Purpose: Despite numerous studies on the optimal treatments for oligometastatic disease (OMD), there is no established interdisciplinary consensus on its diagnosis or classification. This survey-based study aimed to analyze the differential opinions of colorectal surgeons and radiation oncologists regarding the definition and treatment of OMD from the colorectal primary.

Materials and methods: A total of 141 participants were included in this study, consisting of 63 radiation oncologists (44.7%) and 78 colorectal surgeons (55.3%). The survey consisted of 19 questions related to OMD, and the responses were analyzed using the chi-square test to determine statistical differences between the specialties.

Results: The radiation oncologists chose "bone" more frequently compared to the colorectal surgeons (19.2% vs. 36.5%, p=0.022), while colorectal surgeons favored "peritoneal seeding" (26.9% vs. 9.5%, p=0.009). Regarding the number of metastatic tumors, 48.3% of colorectal surgeons responded that "irrelevant, if all metastatic lesions are amendable to local therapy", while only 21.8% of radiation oncologist chose same answer. When asked about molecular diagnosis, most surgeons (74.8%) said it was important, but only 35.8% of radiation oncologists agreed.

Conclusion: This study demonstrates that although radiation oncologists and colorectal surgeons agreed on a majority of aspects such as diagnostic imaging, biomarker, systemic therapy, and optimal timing of OMD, they also had quite different perspectives on several aspects of OMD. Understanding these differences is crucial to achieving multidisciplinary consensus on the definition and optimal management of OMD.

Keywords: Colorectal neoplasms; Colorectal surgeon; Oligometastasis; Radiation oncologists.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

Yong Chan Ahn, the editor-in-chief of the Cancer Research and Treatment, was not involved in the editorial evaluation or decision to publish this article. All remaining authors have declared no conflicts of interest.

Figures

Fig. 1
Fig. 1
Recommended total dose for lung metastasis from colon and rectum in 10-fractions (A) and 4-fractions (B) scheme.
Fig. 2
Fig. 2
Recommended total dose for liver metastasis from colon and rectum in 10-fractions (A) and 4-fractions (B) scheme.
See this image and copyright information in PMC

References

    1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10. - PubMed
    1. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759–66. - PMC - PubMed
    1. Kanas GP, Taylor A, Primrose JN, Langeberg WJ, Kelsh MA, Mowat FS, et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012;4:283–301. - PMC - PubMed
    1. Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21:e18–28. - PubMed
    1. Willmann J, Vlaskou Badra E, Adilovic S, Ahmadsei M, Christ SM, van Timmeren JE, et al. Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: a retrospective single center study. Radiother Oncol. 2022;168:256–64. - PubMed